Lucid Diagnostics Announces Data From ESOGUARD BE-1 Study; Demonstrates 87.5% Sensitivity And 98.6% NPV For EsoGuard Test; Strengthens Clinical Validity For Medicare LCD Pre-Submission And Commercial Payor Engagements; Cleveland VA Study Data Accepted For Peer-Reviewed Publication
Portfolio Pulse from Benzinga Newsdesk
Lucid Diagnostics announced data from the ESOGUARD BE-1 study, showing 87.5% sensitivity and 98.6% NPV for the EsoGuard test. This strengthens the clinical validity for Medicare LCD pre-submission and commercial payor engagements. Additionally, data from the Cleveland VA study has been accepted for peer-reviewed publication.
July 02, 2024 | 11:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lucid Diagnostics' ESOGUARD BE-1 study demonstrated high sensitivity and NPV for the EsoGuard test, enhancing its clinical validity for Medicare LCD pre-submission and commercial payor engagements. Additionally, data from the Cleveland VA study has been accepted for peer-reviewed publication.
The high sensitivity and NPV of the EsoGuard test from the ESOGUARD BE-1 study significantly enhance its clinical validity, which is crucial for Medicare LCD pre-submission and commercial payor engagements. The acceptance of the Cleveland VA study data for peer-reviewed publication further validates the test's credibility.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100